In vitro inhibitory effects of kaempferitrin on human liver cytochrome P450 enzymes

Context: Kaempferitrinis (KF) is a bioactive flavonoid and possesses numerous pharmacological activities. However, whether KF affects the activity of human liver cytochrome P450 (CYP) enzymes remains unclear. Objective: This study investigates the effects of KF on eight major CYP isoforms in human l...

Full description

Bibliographic Details
Main Authors: Ning Zhang, Jing Liu, Zhixia Chen, Wenwen Dou
Format: Article
Language:English
Published: Taylor & Francis Group 2019-01-01
Series:Pharmaceutical Biology
Subjects:
Online Access:http://dx.doi.org/10.1080/13880209.2019.1656257
_version_ 1798032034680012800
author Ning Zhang
Jing Liu
Zhixia Chen
Wenwen Dou
author_facet Ning Zhang
Jing Liu
Zhixia Chen
Wenwen Dou
author_sort Ning Zhang
collection DOAJ
description Context: Kaempferitrinis (KF) is a bioactive flavonoid and possesses numerous pharmacological activities. However, whether KF affects the activity of human liver cytochrome P450 (CYP) enzymes remains unclear. Objective: This study investigates the effects of KF on eight major CYP isoforms in human liver microsomes (HLMs). Materials and methods: In vitro, HLMs were used to investigate the inhibitory effects of KF (100 μM) on the eight human liver CYP isoforms (i.e., 1A2, 3A4, 2A6, 2E1, 2D6, 2C9, 2C19, and 2C8), and corresponding probe substrates were used. Enzyme kinetic studies (0–50 μM of KF) were conducted to determine the inhibition mode of KF on CYP enzymes. Results: The results showed that KF inhibited the activity of CYP1A2, 3A4, and 2C9, with IC50 values of 20.56, 13.87, and 14.62 μM, respectively, but that other CYP isoforms were not affected. Enzyme kinetic studies showed that KF was not only a noncompetitive inhibitor of CYP3A4, but also a competitive inhibitor of CYP1A2 and 2C9, with Ki values of 7.11, 10.24, and 7.58 μM, respectively. In addition, KF is a time-dependent inhibitor for CYP3A4 with KI/Kinact value of 10.85/0.036 min/μM. Discussion: The in vitro studies of KF with CYP isoforms indicate that KF has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP1A2, 3A4, and 2C9. Conclusion: It is recommended that KF should not be used with other drugs metabolized by CYP1A2, 3A4, and 2C9. Further clinical studies are needed to evaluate the significance of this interaction.
first_indexed 2024-04-11T20:06:18Z
format Article
id doaj.art-cbf32919af56482c87b0f4f7be9aea63
institution Directory Open Access Journal
issn 1388-0209
1744-5116
language English
last_indexed 2024-04-11T20:06:18Z
publishDate 2019-01-01
publisher Taylor & Francis Group
record_format Article
series Pharmaceutical Biology
spelling doaj.art-cbf32919af56482c87b0f4f7be9aea632022-12-22T04:05:18ZengTaylor & Francis GroupPharmaceutical Biology1388-02091744-51162019-01-0157157157610.1080/13880209.2019.16562571656257In vitro inhibitory effects of kaempferitrin on human liver cytochrome P450 enzymesNing Zhang0Jing Liu1Zhixia Chen2Wenwen Dou3Yidu Central Hospital of WeifangYidu Central Hospital of WeifangYidu Central Hospital of WeifangAffiliated Hospital of Weifang Medical UniversityContext: Kaempferitrinis (KF) is a bioactive flavonoid and possesses numerous pharmacological activities. However, whether KF affects the activity of human liver cytochrome P450 (CYP) enzymes remains unclear. Objective: This study investigates the effects of KF on eight major CYP isoforms in human liver microsomes (HLMs). Materials and methods: In vitro, HLMs were used to investigate the inhibitory effects of KF (100 μM) on the eight human liver CYP isoforms (i.e., 1A2, 3A4, 2A6, 2E1, 2D6, 2C9, 2C19, and 2C8), and corresponding probe substrates were used. Enzyme kinetic studies (0–50 μM of KF) were conducted to determine the inhibition mode of KF on CYP enzymes. Results: The results showed that KF inhibited the activity of CYP1A2, 3A4, and 2C9, with IC50 values of 20.56, 13.87, and 14.62 μM, respectively, but that other CYP isoforms were not affected. Enzyme kinetic studies showed that KF was not only a noncompetitive inhibitor of CYP3A4, but also a competitive inhibitor of CYP1A2 and 2C9, with Ki values of 7.11, 10.24, and 7.58 μM, respectively. In addition, KF is a time-dependent inhibitor for CYP3A4 with KI/Kinact value of 10.85/0.036 min/μM. Discussion: The in vitro studies of KF with CYP isoforms indicate that KF has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP1A2, 3A4, and 2C9. Conclusion: It is recommended that KF should not be used with other drugs metabolized by CYP1A2, 3A4, and 2C9. Further clinical studies are needed to evaluate the significance of this interaction.http://dx.doi.org/10.1080/13880209.2019.1656257cyp1a2cyp3a4cyp2c9herb-drug interaction
spellingShingle Ning Zhang
Jing Liu
Zhixia Chen
Wenwen Dou
In vitro inhibitory effects of kaempferitrin on human liver cytochrome P450 enzymes
Pharmaceutical Biology
cyp1a2
cyp3a4
cyp2c9
herb-drug interaction
title In vitro inhibitory effects of kaempferitrin on human liver cytochrome P450 enzymes
title_full In vitro inhibitory effects of kaempferitrin on human liver cytochrome P450 enzymes
title_fullStr In vitro inhibitory effects of kaempferitrin on human liver cytochrome P450 enzymes
title_full_unstemmed In vitro inhibitory effects of kaempferitrin on human liver cytochrome P450 enzymes
title_short In vitro inhibitory effects of kaempferitrin on human liver cytochrome P450 enzymes
title_sort in vitro inhibitory effects of kaempferitrin on human liver cytochrome p450 enzymes
topic cyp1a2
cyp3a4
cyp2c9
herb-drug interaction
url http://dx.doi.org/10.1080/13880209.2019.1656257
work_keys_str_mv AT ningzhang invitroinhibitoryeffectsofkaempferitrinonhumanlivercytochromep450enzymes
AT jingliu invitroinhibitoryeffectsofkaempferitrinonhumanlivercytochromep450enzymes
AT zhixiachen invitroinhibitoryeffectsofkaempferitrinonhumanlivercytochromep450enzymes
AT wenwendou invitroinhibitoryeffectsofkaempferitrinonhumanlivercytochromep450enzymes